A Double Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel Group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)

This study is multicenter, double-blinded parallel group design, where participants with
moderate to severe asthma with AFAD will be enrolled. Participants will receive three doses
of 10 milligrams/kilogram (mg/kg) of GSK3772847 every 4 Weeks versus placebo along with
standard of care. Participants will be randomized in 1:1 ratio to receive either 10 mg/kg
GSK3772847 intravenously (IV) or matching placebo IV. Participants will receive study
treatment on Week 0 (Day 1), Week 4 and Week 8. The total duration of the study will be 28
Weeks and approximately 46 participants will be randomized.